BONRAYBIO (6955) reported revenue of NT$32.2 million for Oct 2026, +30.1% year on year and +7.3% from the previous month. Revenue for Jan–Oct 2026 was NT$296 million (+19.0% year on year).
Year-on-year revenue growth: 25+ months in a row. →
In Oct 2026, it ranked No. 116 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$32.2 million | +30.1% | +7.3% |
| Sep 2026 | NT$30 million | +14.5% | -2.3% |
| Aug 2026 | NT$30.7 million | +21.4% | +16.5% |
| Jul 2026 | NT$26.4 million | +21.3% | -21.0% |
| Jun 2026 | NT$33.4 million | +30.1% | +11.2% |
| May 2026 | NT$30 million | +12.6% | +3.9% |
| Apr 2026 | NT$28.9 million | +5.3% | -7.1% |
| Mar 2026 | NT$31.1 million | +20.2% | +15.6% |
| Feb 2026 | NT$26.9 million | +13.0% | +2.0% |
| Jan 2026 | NT$26.4 million | +23.5% | -16.0% |
| Dec 2025 | NT$31.4 million | +29.4% | +20.3% |
| Nov 2025 | NT$26.1 million | +22.0% | +5.5% |
| Oct 2025 | NT$24.7 million | +42.4% | -5.6% |
| Sep 2025 | NT$26.2 million | +36.0% | +3.6% |
| Aug 2025 | NT$25.3 million | +18.2% | +16.4% |
| Jul 2025 | NT$21.7 million | +32.8% | -15.3% |
| Jun 2025 | NT$25.7 million | +65.1% | -3.8% |
| May 2025 | NT$26.7 million | +18.6% | -2.8% |
| Apr 2025 | NT$27.4 million | +65.4% | +6.1% |
| Mar 2025 | NT$25.9 million | +46.7% | +8.7% |
| Feb 2025 | NT$23.8 million | +58.2% | +11.4% |
| Jan 2025 | NT$21.4 million | +37.9% | -12.0% |
| Dec 2024 | NT$24.3 million | +13.1% | +13.4% |
| Nov 2024 | NT$21.4 million | +39.4% | +23.1% |
| Oct 2024 | NT$17.4 million | +20.3% | -9.8% |
Jan–Oct 2026 cumulative: NT$296 million (+19.0% YoY)
Other Biotech & Medical companies
Compare with peers: BONRAYBIO vs PEC / BONRAYBIO vs Lotus Pharm / BONRAYBIO vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16